Inactive Instrument

News Blue Water Ventures International Inc Other OTC

Equities

US8317182009

End-of-day quote Other OTC Other stock markets
- ^USD	-

2023	Psycheceutical Bioscience, Inc. Announces Chief Executive Officer Changes	CI
2023	Psycheceutical Bioscience, Inc. Appoints Neilank K. Jha as Its New Executive Chairman	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Psycheceutical Bioscience, Inc. Announces Chief Executive Officer Changes	Dec. 12	CI
Psycheceutical Bioscience, Inc. Appoints Neilank K. Jha as Its New Executive Chairman	Dec. 12	CI
Blue Water Ventures International, Inc. announced that it expects to receive $5 million in funding	23-09-25	CI
Psycheceutical Bioscience, Inc Announces First Patient Has Been Dosed in Its Phase I Study to Evaluate Its Patented Neurodirectâ„¢ Ketamine Topical Delivery System for the Treatment of Post Traumatic Stress Disorder	23-07-13	CI
Veru Sells ENTADFI Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones	23-04-21	AQ
Psycheceutical Bioscience, Inc. Named a 2023 Top 10 Biotech Startup by Life Sciences Review	23-04-13	PR
Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab	23-03-29	GL
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD	23-03-21	GL
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD	23-03-21	AQ
Psycheceutical Bioscience, Inc. Announces Publication of Pre-Clinical Observational Data Supports Potential of its NeuroDirect™ Ketamine Topical Cream as Treatment for PTSD	23-03-21	CI
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD	23-02-15	GL
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD	23-02-15	AQ
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD	23-02-15	CI
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD	23-02-02	GL
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD	23-02-02	AQ
Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD	23-01-26	GL
Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD	23-01-26	AQ
Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer	23-01-10	GL
Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer	23-01-10	AQ
Dr. Aric Logsdon Joins Psycheceutical Bioscience, Inc. as Company’s Scientific Director	22-11-29	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Blue Water Ventures International Inc Other OTC

Equities

US8317182009

Summary

Filters